Teprotumumab-trbw
(Redirected from Tepezza)
What is Teprotumumab-trbw?[edit | edit source]
- Teprotumumab-trbw (TEPEZZA) is an insulin-like growth factor-1 receptor inhibitor.
What are the uses of this medicine?[edit | edit source]
- This medicine is used for the treatment of Thyroid Eye Disease.
How does this medicine work?[edit | edit source]
- Teprotumumab-trbw's mechanism of action in patients with Thyroid Eye Disease has not been fully characterized.
- Teprotumumab-trbw binds to IGF-1R and blocks its activation and signaling.
Who Should Not Use this medicine ?[edit | edit source]
- This medicine have no usage limitations.
Is this medicine FDA approved?[edit | edit source]
- It was approved for use in the United States in 2020.
How should this medicine be used?[edit | edit source]
Recommended Dosage
- The recommended dose of TEPEZZA is an intravenous infusion of 10 mg/kg for the initial dose followed by an intravenous infusion of 20 mg/kg every three weeks for 7 additional infusions.
Administration
- Administer the diluted solution intravenously over 90 minutes for the first two infusions.
- If well tolerated, the minimum time for subsequent infusions can be reduced to 60 minutes.
- If not well tolerated, the minimum time for subsequent infusions should remain at 90 minutes.
- Do not administer as an intravenous push or bolus.
- TEPEZZA should not be infused concomitantly with other agents.
What are the dosage forms and brand names of this medicine?[edit | edit source]
This medicine is available in fallowing doasage form:
- As Injection: 500 mg lyophilized powder in a single-dose vial for reconstitution
This medicine is available in fallowing brand namesː
- TEPEZZA
What side effects can this medication cause?[edit | edit source]
The most common side effects of this medicine include:
- muscle spasm
- nausea
- alopecia
- diarrhea
- fatigue
- hyperglycemia
- hearing impairment
- dry skin
- dysgeusia
- headache
What special precautions should I follow?[edit | edit source]
- Infusion reactions may occur.If an infusion reaction occurs, interrupt or slow the rate of infusion and use appropriate medical management.
- Monitor patients with preexisting Inflammatory Bowel Disease (IBD) for flare of disease; discontinue TEPEZZA if IBD worsens.
- This medicine may cause hyperglycemia.
- Monitor glucose levels in all patients; treat hyperglycemia with glycemic control medications.
What to do in case of emergency/overdose?[edit | edit source]
- No information is available for patients who have received an overdosage.
Can this medicine be used in pregnancy?[edit | edit source]
- There are insufficient data with TEPEZZA use in pregnant women to inform any drug associated risks for adverse developmental outcomes.
Can this medicine be used in children?[edit | edit source]
- Safety and effectiveness have not been established in pediatric patients.
What should I know about storage and disposal of this medication?[edit | edit source]
- Refrigerate at 2°C to 8°C (36°F to 46°F) in original carton until time of use to protect from light. Do not freeze.
Teprotumumab-trbw Resources | |
---|---|
|
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Deepika vegiraju